Bristol-Myers Squibb Company
Phyllis R Yale (Director) reports BMY insider transactions
About this filing
Bristol-Myers Squibb Company (BMY) filed Form 4 (insider transaction) with the SEC on Oct 2, 2026. Form 4 reports a company insider’s trades in the company’s shares.
Key facts
- Insider
- Phyllis R Yale · Director
| Date | Transaction | Shares | Price | Value | Held after | Ownership |
|---|---|---|---|---|---|---|
| Sep 30, 2026 | A · grantDeferred Share UnitsFootnotes F1, F2 | +560.897 | $62.40 | $34,999.97 | 45,980.077 | Direct |
Footnotes
- F1 Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.
- F2 Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
More BMY filings
- 10-Q
Filed Oct 29, 2026
- 8-K
Filed Oct 29, 2026
- 4
Filed Oct 5, 2026
- 4
Filed Oct 2, 2026
- 4
Filed Oct 2, 2026
- 4
Filed Oct 2, 2026
Not investment advice. Summaries can contain errors; the SEC filing is the official record.